Therapeutic Candidate Articles & Analysis
10 articles found
By fostering an environment of innovation and collaboration, Alfa Cytology not only advances its therapeutic candidates but also contributes to the broader field of cancer research. ...
This stability makes them suitable candidates for therapeutic use and allows for diverse storage conditions. ...
These advancements not only enhance our understanding of the disease but also pave the way for more targeted therapeutic solutions. Tumor models for breast cancer, which include both in vivo and in vitro systems, are crucial for studying the complexities of tumor biology and testing potential treatments. ...
This not only integrates the advantages of various methods but also accelerates the early discovery stage of therapeutic development. In situations where computer simulation analysis and AI-driven antibody discovery run parallel to in vivo methods, we are expected to predict and prioritize potential antibody candidates. ...
We tend to be so specialized that it’s difficult to fund a team bringing the necessary expertise together to push potential therapeutics along the pathway. I knew it would be incredibly rewarding to see these two lead a company and carry out their vision. ...
Antibodies that target ICPI such as PD-1, PD-L1 and CTLA4 have been generated which have therapeutic efficacy in NSCLC and other tumors. Unfortunately, only a minority of patients respond to these therapies and the responses are often not durable. ...
Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical trial designed to ...
Insilico Medicine announced the nomination of a novel preclinical therapeutic candidate for treating COVID-19, designed using the generative chemistry AI platform Chemistry42. The new drug candidate is a 3CL protease inhibitor unique from existing drugs in its class because it can be rapidly produced. ...
This study describes the functional kinomic landscape of Ras/p53 mutant chemically-induced squamous cell carcinoma in both the baseline unperturbed state and following DNA damage and nominates candidate therapeutic targets, including the Nek4 kinase, for further development. ...
Here we outline how machine learning, advances in viral immunology, and high-throughput measurements can enable engineering of a new generation of de-immunized capsids beyond the antigenic landscape of natural AAVs, towards expanding the therapeutic reach of gene therapy. Introduction Recently approved AAV-based therapeutics and numerous ...